Stock dilution is on the way for the small biotech.
News & Analysis: Gossamer Bio
GOSS earnings call for the period ending March 31, 2020.
Novartis is throwing in the towel on a drug similar to Gossamer's lead candidate.
GOSS earnings call for the period ending September 30, 2019.
Fresh off an initial public offering, the pharmaceutical company has taken investors on a wild ride.
Investors weren't exactly sure how to react to the clinical failure of a drug that works similarly to Gossamer's lead candidate.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
GOSS earnings call for the period ending June 30, 2019.
GOSS earnings call for the period ending March 31, 2019.